Capsule Summary Slidesets

Share

Program Content

Activities

  • Ven + Aza in Poor-Risk AML
    Pooled Analysis of Impact of TP53 Mutations on Efficacy of Venetoclax + Azacitidine in Patients With AML and Poor-Risk Cytogenetics
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • ASCEMBL 48-week update
    ASCEMBL: 48-Wk Update of Results From the Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2TKIs
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • CPX-351 or HMA + Ven in AML
    CPX-351 and HMA + Venetoclax as Frontline Therapy in AML: A Retrospective Comparative Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • Venetoclax/Decitabine in Adverse-Risk AML
    Venetoclax/Decitabine for Young Adults With Newly Diagnosed ELN Adverse-Risk AML: Phase II Trial Interim Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2021

    Expires: December 12, 2022

  • GMALL 08/2013
    GMALL 08/2013: First Results From the Risk-Adapted, MRD-Stratified Trial in Adults With Newly Diagnosed ALL/LBL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • QUIZ/VEN/DAC in <i>FLT3</i>-Mutated AML
    Evaluation of Quizartinib With Venetoclax and Decitabine Therapy in Patients With Newly Diagnosed or R/R FLT3-Mutated AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • Aza/Ven/Magrolimab in AML
    Combination Therapy With Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • Low-Dose Dasatinib in CP-CML
    Low-Dose Dasatinib vs Standard-Dose Dasatinib in Newly Diagnosed CP-CML: A Propensity Score Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • Gilteritinib + Venetoclax in R/R AML
    Phase Ib Study of Gilteritinib Combined With Venetoclax for R/R Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • AGILE: Ivosidenib/AZA in AML
    AGILE: Phase III Trial of Ivosidenib + Azacitidine vs Placebo + Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • LACEWING
    LACEWING: Phase III Study of Gilteritinib + Azacitidine vs Azacitidine for Patients With Newly Diagnosed FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation